|
|
- Daniella Wood
- 5 years ago
- Views:
Transcription
1 C M Y CM MY CY CMY K Co nf e r e nc e D e t a il s 8
2 6 th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease 5-7 March 2009 Granada Spain Granada Congress & Exhibition Centre Supported by Novartis Pharmaceutical Corporation and Ipsen Beaufour
3 Welcome to Granada The ENETS Executive Committee extends a warm welcome to its 6th Annual Conference in Granada, Spain. In attending this meeting, you join some of the most respected and dynamic researchers and key opinion leaders in the field of neuroendocrine tumor research. Over the next two days, they will be detailing the most relevant and significant advances in the field today. Our aim is to give you beneficial lessons to help you in your daily clinical practice. On behalf of the scientific organizing committee, I welcome you to Granada. The city is a highly appropriate place to hold our conference: its legacy of blended cultures mirrors our Society s mission in fostering international cooperation toward solving the complex clinical problems neuroendocrine tumors present. The Society today claims more than 550 members, hailing from 48 countries this is a proud achievement for a research society dedicated to a rare disease, and one founded only five years ago. Again, I welcome all participants to our annual meeting and appreciate the distances traveled to be here. Our 2008 conference in Paris received very positive reviews and we hope that the Granada meeting will be just as rewarding. In inviting the conference lecturers, we hope to exhibit the Society s work of this past year, including the ENETS Guidelines for the Standards of Care. But we also felt it important to add some new aspects to the program. This would encompass poorly differentiated endocrine carcinomas, novel approaches to NET treatment, and a session on combined therapy and clinical trials. We also have expanded the program to include an additional session for clinical research abstracts. I am exceptionally proud to announce that we received 119 abstracts for the meeting. The growth in NET research, as well as the continued increase in membership registrations and abstract submissions, speaks for itself and our future work in the field. The ENETS Annual Conference this year is sponsored by the pharmaceutical firms Novartis, as platinum sponsor, and Ipsen, as silver sponsor. I would like to take this opportunity to thank both for their continued support for and interest in ENETS. I would also like to thank the companies CISBIO, Covidien, ITG Isotope Technologies Garching and Sirtex, which are exhibiting during the conference. I welcome each of you to Granada and to the ENETS 6th Annual Conference. Guido Rindi, M.D., Ph.D. Parma, Italy Chairman, European Neuroendocrine Tumor Society (ENETS) 2
4 Saturday, 7 March :30-09:30 SESSION 5: Liver Metastases Chairs: D. O Toole, Dublin, IRL D. J. Kwekkeboom, Rotterdam, NED 08:30-08:50 Key Players in Metastases Development D. R. Welch, Birmingham, AL, 08:50-09:10 Surgery and Ablation T. Steinmüller, Berlin, 09:10-09:30 Medical Treatment K. Öberg, Uppsala, 09:30-10:15 SELECTED ABSTRACTS (III): Basic/Translational Research Chairs: M. Caplin, London, U.-F. Pape, Berlin, 09:30-09:45 Molecular predictors of response to chemotherapy in advanced/metastatic gastroenteropancreatic endocrine tumors A. Couvelard, Clichy, 09:45-10:00 Adenosine A2 receptor signalling mediates chromogranin A secretion from neuroendocrine tumors A. Kalhan, Cardiff, 10:00-10:15 Dual expression of alpha-internexin in pancreatic endocrine tumors and its implications M. Mei, Beijing, CHN 10:15-10:45 COFFEE BREAK 10:45-11:00 Young Investigator Awards G. Kaltsas, Athens, GRE G. Rindi, Parma, 11:00-12:30 SESSION 6: Combined Therapy and Clinical Trials Chairs: B. Kos-Kud a, Zabrze, POL M. Kulke, Boston, MA, 11:00-11:30 Hot-Off-the-Press Results of Ongoing Trials in the EU and the C. Lombard-Bohas, Lyon, J. Yao, Houston, TX, 11:30-12:00 Single or Monotherapy: Need for Combinations? L. Kvols, Tampa, FL, 12:00-12:30 Basic Evidence for Future Trials E. Van Cutsem, Leuven, BEL 12:30-12:50 Lessons from Granada R. Jensen, Bethesda, MD, 12:50-13:00 Concluding Remarks G. Rindi, Parma, END OF MEETING Mark Your Calendars Now! 7 th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumors For more information, visit: March 2010 Berlin Germany Session 5 Abstracts 3 Session 6 6th Annual ENETS Conference 7 March
5 C Y CM MY CY CMY K Conference organization: Scientific organizing committee: ENETS Coordinating Office c/o Charité - University Hospital Campus Virchow-Klinikum Hepatology and Gastroenterology Augustenburger Platz Berlin, Germany Martyn Caplin London Wouter de Herder Rotterdam NED Barbro Eriksson Uppsala Dermot O Toole Dublin IRL tel +49 (0) / fax +49 (0) Guido Rindi Parma Philippe Ruszniewski Clichy Bertram Wiedenmann Berlin office@neuroendocrine.net 4 M
6 Friday, 6 March :30-10:30 SESSION 2: Various localizations, various problems Chairs: W. de Herder, Rotterdam, NED G. Delle Fave, Rome, 08:30-09:00 Lung E. Baudin, Villejuif, 09:00-09:30 Pancreas M. Mallath, Mumbai, IND 09:30-10:00 Rectum J. Ramage, Basingstoke, 10:00-10:30 Ileum F. Costa, Sao Paulo, BRA 10:30-11:00 ENETS Life Achievement Award Chair: G. Rindi, Parma, Recipient: R. Arnold, Marburg/Munich, Dedication: B. Wiedenmann, Berlin, 11:00-11:30 COFFEE BREAK 11:30-12:30 SESSION 3: Poorly Differentiated Endocrine Carcinomas Chairs: L. Kvols, Tampa, FL, ; P. Komminoth, Zürich, SUI 11:30-11:50 Diagnosis O. Nilsson, Gothenborg, 11:50-12:10 Therapy and Management (I): Surgery H. Ahlman, Gothenborg, 12:10-12:30 Therapy and Management (II): Medical Treatment J. Yao, Houston, TX, 12:30-14:00 LUNCH 14:00-15:15 SELECTED ABSTRACTS (II): Clinical Research Chairs: R. V. Thakker, Oxford, D. Ferone, Genoa, 14:00-14:15 Prevalence and features of MEN1 in a large cohort of gastroenteropancreatic and thoracic NET: data from a large multicentric Italian database P. Ferolla, Perugia, 14:15-14:30 Clinical results of PRRT with 90 Y-DOTATATE and 90 Y/ 177 Lu- DOTATATE - what is better for therapy? L. Krolicki, Warsaw, POL 14:30-14:45 Chemotherapy with 5-Fluorouracil, cisplatin and streptozocin (FCiSt) for neuroendocrine tumors T. Meyer, London, 14:45-15:00 Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group A. Rinke, Marburg, 15:00-15:15 First line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide J. Strosberg, Tampa, FL, 15:15-16:15 SESSION 4: Surgery, Established Techniques and Novel Approaches Chairs: R. Kianmanesh, Colombes, B. Eriksson, Uppsala, 15:15-15:35 Lung E. Lim, London, 15:35-15:55 Gut I. Modlin, New Haven, CT, 15:55-16:15 Pancreas A. Sauvanet, Clichy, 16:15-17:00 Poster Viewing 17:00 SATELLITE SYMPOSIA Session 3 Session 2 Abstracts 2 Session 4 6th Annual ENETS Conference 6 March
7 C M Y CM MY CY CMY K SESSION PARTICIPANTS H. Ahlman, Gothenborg G. Åkerström, Gothenborg R. Arnold, Munich E. Baudin, Villejuif M. Caplin, London F. Costa, Sao Paulo W. de Herder, Rotterdam G. Delle Fave, Rome B. Eriksson, Uppsala D. Ferone, Genoa A. Grossman, London R. Jensen, Bethesda, MD G. Kaltsas, Athens R. Kianmanesh, Colombes P. Komminoth, Zürich B. Kos-Kud a, Zabrze M. Kulke, Boston, MA L. Kvols, Tampa, FL D. Kwekkeboom, Rotterdam E. Lim, London BRA NED GRE SUI POL NED C. Lombard-Bohas, Lyon M. Mallath, Mumbai I. Modlin, New Haven, CT O. Nilsson, Gothenborg K. Öberg, Uppsala D. O Toole, Dublin U.-F. Pape, Berlin U. Plöckinger, Berlin J. Ramage, Basingstoke G. Rindi, Parma P. Ruszniewski, Clichy H. Sasano, Sendai A. Sauvanet, Clichy T. Steinmüller, Berlin R. V. Thakker, Oxford E. Van Cutsem, Leuven D. R. Welch, Birmingham, AL B. Wiedenmann, Berlin J. Yao, Houston, TX IND IRL JAP BEL J. Ardill, Belfast A. Astudillo, Oviedo R. Bettini, Verona P. Brown, The Woodlands, TX ESP A. Couvelard, Clichy A. Kalhan, Cardiff L. Krolicki, Warsaw M. Mei, Beijing T. Meyer, London A. Rinke, Marburg J. Strosberg, Tampa, FL POL CHN ABSTRACT PRESENTERS A. Falchetti, Florence P. Ferolla, Perugia 6
8 ADVANCE REGISTRATION: Wednesday, 4 March 2009, 16:00 18:00 Conference participants can register the evening before the conference begins in the entrance lobby of the Granada Congress & Exhibition Centre. Thursday, 5 March :00-13:00 REGISTRATION 13:00-13:20 Welcome and Introduction G. Rindi, ENETS Chairman, Parma, 13:20-14:30 SESSION 1: Standards of Care Chairs: U. Plöckinger, Berlin, A. Grossman, London, 13:20-13:35 Introduction U. Plöckinger, Berlin, 13:35-13:55 Diagnosis B. Eriksson, Uppsala, 13:55-14:15 Medical Therapy P. Ruszniewski, Clichy, 14:15-14:30 Surgical Therapy G. Åkerström, Gothenborg, 14:30-15:00 COFFEE BREAK 15:00-16:15 Selected Abstracts (I): Clinical Research Chairs: G. Kaltsas, Athens, GRE H. Sasano, Sendai, JAP 15:00-15:15 Assessment of the sensitivity of circulating neurokinin A and chromogranin A to changing prognosis in patients with serotoninproducing endocrine tumors of the ileum and colon J. Ardill, Belfast, 15:15-15:30 Snail as epithelial-mesenchymal transition marker in neuroendocrine tumors of the lung A. Astudillo, Oviedo, ESP 15:30-15:45 Non-functioning pancreatic endocrine tumors: Any correlation of tumor size with malignancy? R. Bettini, Verona, 15:45-16:00 LX1032: A novel approach for managing gastrointestinal symptoms in carcinoid syndrome P. Brown, The Woodlands, TX, 16:00-16:15 Early identification of the MEN1-associated gastrinomas: Use of the secretin test in the experience of the Center for Hereditary Endocrine Tumors of Florence, Italy A. Falchetti, Florence, 16:15-17:15 Poster Viewing 17:15-18:15 ENETS General Assembly 18:15 WELCOME RECEPTION Session 1 Abstracts I 6th Annual ENETS Conference 5 March
A Newsletter for Medical Professionals and ENETS Members
A Newsletter for Medical Professionals and ENETS Members Summer 2009 The European Neuroendocrine Tumor Society (ENETS) Executive Committee: Chairman: Guido Rindi, Parma, Italy Vice-Chairman: Wouter de
More information10 th Annual ENETS Conference
10 th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease 6-8 March 2013 Barcelona P R E L I M I N A R Y P R O G R A M 1 Scientific Organizing Committee Martyn Caplin,
More informationPreliminary Conference Program
Preliminary Conference Program Contents Scientific Organizing Committee... 1 ENETS Scientific Conference Program... 2 09.03.2016... 2 ENETS Postgraduate Course... 2 Welcome Reception... 3 10.03.2016...
More informationENETS Consensus Guidelines for the Standard of Care in
Neuroendocrinology (DOI:10.1159/000457957) (Accepted, unedited article not yet assigned to an issue) Advanced Release: February 11, 2017 2017 S. Karger AG, Basel www.karger.com/nen Received: December 12,
More informationA Newsletter for Medical Professionals and ENETS Members
Spring/Summer 2007 The European Neuroendocrine Tumor Society (ENETS) Executive Committee: Chairman: Wouter de Herder, Rotterdam, The Netherlands Vice-Chairman: Bertram Wiedenmann, Berlin, Germany Treasurer:
More informationA Newsletter for Medical Professionals and ENETS Members
Spring/Summer 2010 The European Neuroendocrine Tumor Society (ENETS) Executive Committee: Chairman: Philippe Ruszniewski, Clichy, France Vice-Chairman: Guido Rindi, Rome, Italy Chairman-Elect: Kjell Öberg,
More informationPreliminary Conference Program
Preliminary Conference Program Table of Contents ENETS Scientific Conference Program... 4 09.03.2016... 4 ENETS Postgraduate Course... 4 Welcome Reception... 5 10.03.2016... 6 Meet the Professor... 6 Welcome
More informationCLICK TO GO BACK TO KIOSK MENU
Clinical outcomes in patients with baseline renal dysfunction in the NETTER- Study: 77 Lu-DOTATATE vs. high dose octreotide in progressive midgut neuroendocrine tumors J. Strosberg, E. Wolin 2, B. Chasen
More informationReview of Gastrointestinal Carcinoid Tumors: Latest Therapies
Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA Neuroendocrine
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationISRAELI NEUROENDOCRINE TUMORS PROGRAM
th THE 4 1 ISRAELI NEUROENDOCRINE TUMORS (INET) CONGRESS 11.10.2018-13.10.2018 Crown Plaza Hotel, the Dead Sea PROGRAM Thursday, 11.10.2018 15:00-15:30 Registration 15:30-15:50 Opening Remarks 15:50-16:50
More informationToward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives
Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Moderator: Ashley Grossman, MD, FRCP Professor of Neuroendocrinology William Harvey Research Institute Barts
More informationRecent developments of oncology in neuroendocrine tumors (NETs)
Recent developments of oncology in neuroendocrine tumors (NETs) Marc Peeters MD, PhD Coordinator Multidisciplinary Oncological Center Antwerpen (MOCA) Head of the Oncology Department UZA, Professor in
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationTRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS
TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS Jaume Capdevila Unitat de Tumors GI i Endocrins Hospital Universitari Vall d Hebron Barcelona Experts, acollidors i solidaris OUTLINE BACKGROUND
More informationUpdates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010
HIGHLIGHT ARTICLE Updates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010 Susan Alsamarai 1, Steven K Libutti 2, Muhammad Wasif Saif
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationA Newsletter for Medical Professionals and ENETS Members
A Newsletter for Medical Professionals and ENETS Members Summer/Fall 2013 The European Neuroendocrine Tumor Society (ENETS) Executive Committee: Chairman: Kjell Öberg, Uppsala, Sweden Vice-Chairman: Philippe
More informationNICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Neuro-endocrine Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationISRAELI NEUROENDOCRINE TUMORS PROGRAM
1 rd THE 3 ISRAELI NEUROENDOCRINE TUMORS (INET) CONGRESS 22.09.2016-24.09.2016 Crown Plaza Hotel, The Dead Sea PROGRAM Thursday, 22.09.2016 15:00-15:30 Registration 15:30-15:50 Opening Remarks 15:50-16:50
More informationENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
ENETS Consensus Guidelines Published online: January 5, 2016 ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas R. Garcia-Carbonero a H.
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationCrown Plaza Hotel, the Dead Sea PROGRAM
1 THE 4 th ISRAELI NEUROENDOCRINE TUMORS (INET) CONGRESS 11.10.2018-13.10.2018 Crown Plaza Hotel, the Dead Sea PROGRAM Thursday, 11.10.2018 15:00-15:30 Registration 15:30-15:50 Opening Remarks: Dr. Simona
More informationTeresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal
Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Incidence per 100,000 EPIDEMIOLOGY Incidence rates of neuroendocrine tumors by primary tumor site 1.4 1.2 1.0 0.8 0.6
More informationENETS Aims & Key Dates... 5 Welcome Letter from the ENETS Chairman... 7 EACCME - UEMS Accreditation Statement
XXXXXXXXX XXXXXXXX 2 Footnotes Table of Contents ENETS Aims & Key Dates... 5 Welcome Letter from the ENETS Chairman... 7 EACCME - UEMS Accreditation Statement 2017... 9 INTRODUCTION General Information...
More informationENETS Consensus Guidelines. Neuroendocrinology 2016;103: DOI: /
Consensus Guidelines Published online: January 5, 2016 Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and
More informationColor Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging
Saturday, November 5, 2005 8:30-10:30 a. m. Poorly Differentiated Endocrine Carcinomas Chairman: E. Van Cutsem, Leuven, Belgium 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders:
More informationfor the Diagnosis and Treatment of Neuroendocrine Tumor Disease 6-8 March 2019 Barcelona Spain
16th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease 6-8 March 2019 Barcelona Spain PRELIMINARY SCIENTIFIC PROGRAM Scientific Organizing Committee 2 Anne Couvelard
More information*Bert Bakker was an employee of Novartis Pharmaceuticals Corporation until June 06, 2014.
Page 1 of 20 Accepted Preprint first posted on 15 September 2015 as Manuscript ERC-15-0314 1 2 Efficacy of Octreotide LAR in Neuroendocrine Tumors: RADIANT-2 Placebo Arm Post Hoc Analysis 3 4 Authors:
More information2015: Year in Review Results of Recent Trials
2015: Year in Review Results of Recent Trials Pamela L. Kunz, MD Assistant Professor of Medicine / GI Oncology Director, Stanford NET Program Stanford University School of Medicine Disclosures Research
More information3. ITLT Essen 2013 Interdisciplinary Treatment of Liver Tumors April 18-20, 2013 Essen, Germany
3. ITLT Essen 2013 Interdisciplinary Treatment of Liver Tumors April 18-20, 2013 Essen, Germany Scientific Program Thursday, 18th April 2013 HR Thursday, 18th April 08:00 Breakfast Symposia 09:00 Registration
More informationENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms
Consensus Guidelines Published online: January 5, 2016 Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms J.K. Ramage a W.W. De Herder b G. Delle Fave c P. Ferolla d D. Ferone e T. Ito
More informationConsensus guidelines for high grade gastro entero pancreatic (GEP) neuroendocrine tumours and neuroendocrine carcinomas (NEC)
Neuroendocrinology (DOI:10.1159/000443172) (Accepted, unedited article not yet assigned to an issue) Advanced Release: January 5, 2016 2016 S. Karger AG, Basel www.karger.com/nen Received: Accepted after
More informationLetter from the Chairman (Dermot O Toole)
Letter from the Chairman (Dermot O Toole) Dear Friends and Colleagues, Prof. Dermot O Toole, ENETS Chairman It is a great honour to have tak en over the role as Chairman of ENETS at our last annual meeting
More informationDiagnosis and workup of 522 consecutive patients with neuroendocrine neoplasms in Switzerland
Published 19 February 2014, doi:10.4414/smw.2014.13924 Cite this as: Diagnosis and workup of 522 consecutive patients with neuroendocrine neoplasms in Switzerland Marine Gouffon a, Samuel Iff b, Katrin
More information5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition
5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition SIXTH DRAFT OF THE PROGRAM AUGUST 28, 2014 Wednesday, October 5, 2016 08:00-16:30 Post Graduate course (To be developed by the
More informationPrognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours Ulrich-Frank Pape 1 *, Uta Berndt 1 *, Jacqueline Müller-Nordhorn 2, Michael Böhmig 1,4, Stephanie Roll 2, Martin
More informationOPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS
OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS Dr Mairéad McNamara Senior lecturer, University of Manchester & Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust
More informationsymposium article Gastrointestinal neuroendocrine tumors K. E. Öberg* introduction and epidemiology diagnosis symposium article biochemical markers
21 (Supplement 7): vii72 vii80, 2010 doi:10.1093/annonc/mdq290 Gastrointestinal neuroendocrine tumors K. E. Öberg* Department of Endocrine Oncology, University Hospital, SE-751 85 Uppsala, Sweden Gastrointestinal
More informationESSO Course on Diagnosis and Treatment of Pancreatic NeuroEndocrine Tumours (PNETs)
ESSO Course on Diagnosis and Treatment of Pancreatic NeuroEndocrine Tumours (PNETs) 26-27 May 2016 LONDON (UK) ESSO Course on Diagnosis and Management of Pancreatic Neuro-Endocrine Tumours (PNETs) Chairs
More informationTherapeutic Radiopharmaceuticals in Oncology
Therapeutic Radiopharmaceuticals in Oncology Policy Number: 6.01.60 Last Review: 9/2018 Origination: 9/2018 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationNET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ
NET εντέρου Τι νεότερο/ Νέες μελέτες Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET: A Diverse Group of Malignancies 1-3 Wide spectrum of malignancies arising in neuroendocrine cells throughout the body
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL NEUROENDOCRINE GASTRO-ENTERO-PANCREATIC TUMOURS GI Site Group Neuroendocrine gastro-entero-pancreatic tumours Authors: Dr.
More information9. Pharmacological therapy of neuroendocrine tumors
Tumori, 96: 847-857, 2010 9. Pharmacological therapy of neuroendocrine tumors Anja Rinke, Sergio Ricci, Emilio Bajetta, and Svetislav Jelic Evolving perspectives on antiproliferative effects of octreotide
More informationGastrinoma: Medical Management. Haley Gallup
Gastrinoma: Medical Management Haley Gallup Also known as When to put your knife down Gastrinoma Definition and History Diagnosis Historic Management Sporadic vs MEN-1 Defining surgical candidates Nonsurgical
More informationResearch Article ENETS TNM Staging Predicts Prognosis in Small Bowel Neuroendocrine Tumours
ISRN Oncology Volume 2013, Article ID 420795, 7 pages http://dx.doi.org/10.1155/2013/420795 Research Article ENETS TNM Staging Predicts Prognosis in Small Bowel Neuroendocrine Tumours Rajaventhan Srirajaskanthan,
More informationLu 177-Dotatate (Lutathera) Therapy Information
Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine
More informationSS2015 ANNUAL REGISTER AT SSO2015.ORG BY JANUARY 10 AND SAVE. March Houston, TX CANCER SYMPOSIUM #SSO2015TX
SS2015 ANNUAL CANCER SYMPOSIUM March 25-28 Houston, TX REGISTER AT SSO2015.ORG BY JANUARY 10 AND SAVE. #SSO2015TX JOIN THE TOP MINDS IN SURGICAL ONCOLOGY AT SSO 2015 On behalf of SSO President Ronald J.
More informationENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms
Consensus Guidelines Published online: January 19, 2016 Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms G. Delle Fave a D. O Toole b A. Sundin c B. Taal d P. Ferolla e J.K. Ramage
More informationChromogranin A as a predictor of radiological disease progression in neuroendocrine tumours
Original Article Page 1 of 7 Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours Roberta Elisa Rossi 1,2, Jorge Garcia-Hernandez 1, Tim Meyer 3, Christina Thirlwell
More informationGI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust
GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust Introduction Carcinoid was old term, introduced in 1906 by German pathologist Cancinoma like More recent
More informationUnited States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment
Online Submissions: http://www.wjgnet.com/esps/ wjg@wjgnet.com doi:10.3748/wjg.v19.i15.2348 World J Gastroenterol 2013 April 21; 19(15): 2348-2354 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2013 Baishideng.
More informationSunitinib Achieved Fast and Sustained Control of VIPoma. Symptoms
Page 1 of 13 Accepted Preprint first posted on 10 October 2014 as Manuscript EJE-14-0682 1 1 Case report 2 3 4 Sunitinib Achieved Fast and Sustained Control of VIPoma Symptoms 5 6 7 Louis de Mestier 1,
More informationLetter from the Chairman
Summer 2015 Letter from the Chairman Dear colleagues and friends, This last year has seen major changes within the structure and workings of ENETS as well as significant advances in our goals as a clinical
More informationA New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy
RADIONUCLIDE THERAPY AND ALLIED SCIENCE President: Giovanni Paganelli Chairman: Maria Salvato Baltimore USA Domenico Barone Meldola Italy A New Proposal for Metabolic Classification of NENs Stefano Severi
More informationPoorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin
ENETS Guidelines DOI: 10.1159/000109976 Published online: October 16, 2007 Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin Hak an Ahlman a Ola Nilsson b Anne M. McNicol c Philippe
More informationAdvanced typical and atypical carcinoid tumours of the lung: management recommendations
REVIEW ARTICLE Advanced typical and atypical carcinoid tumours of the lung: management recommendations B. Melosky md* ABSTRACT Background Neuroendocrine tumours (nets) are classified by site of origin,
More informationENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation
Conference Report Neuroendocrinology 2017;105:310 319 Received: November 8, 2016 Accepted after revision: January 24, 2017 Published online: February 17, 2017 ENETS Consensus Recommendations for the Standards
More informationConsensus guidelines update for colorectal neuroendocrine
Neuroendocrinology (DOI:10.1159/000443166) (Accepted, unedited article not yet assigned to an issue) Advanced Release: January 5, 2016 2016 S. Karger AG, Basel www.karger.com/nen Received: Accepted after
More informationLink and Lead A look in the future and the role of transplant coordinators.
TRANSPLANTATION LEARNING JOURNEY Munich, Germany 6-10 2018 Second announcement 6-7 10 th ELITA 6-7 VCA 7 3 rd ETAHP 7-8 27 th 27 th Congress 3 rd Congress & Workshops Workshops 8 9-10 3 rd 9-10 Link and
More informationA Comprehensive Guide for 2014 SPONSORSHIP & UNDERWRITING Programs and Services
A Comprehensive Guide for 2014 SPONSORSHIP & UNDERWRITING Programs and Services Sponsorship and Underwriting Programs and Services Mission to Care. Vision to Lead. There is no organization better positioned
More information14th International Workshop Multiple Endocrine Neoplasia and other rare endocrine tumors. September 25 27, Vienna - Austria.
14th International Workshop Multiple Endocrine Neoplasia and other rare endocrine tumors September 25 27, 2014 Vienna - Austria Congress Venue Gesellschaft der Ärzte in Wien - Billrothhaus Frankgasse 8,
More informationSelection of Appropriate Treatment
Expert Review in Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Selection of Appropriate Treatment Reference Slide Deck Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies
More informationPROVISIONAL SCIENTIFIC PROGRAMME AND TIMETABLE
PROVISIONAL SCIENTIFIC PROGRAMME AND TIMETABLE Thursday 17 th October, 2013 09.00- : Executive meetings (only for the Executive and the International Advisory Boards of EURIPA and the Executive of EGPRN),
More informationENETS Aims & Key Dates... 5 Welcome Letter from the ENETS Chairman... 7 EACCME - UEMS Accreditation Statement
XXXXXXXXX XXXXXXXX 2 Footnotes Table of Contents ENETS Aims & Key Dates... 5 Welcome Letter from the ENETS Chairman... 7 EACCME - UEMS Accreditation Statement 2018... 9 INTRODUCTION General Information...
More informationNeuroendocrine Tumors: Treatment Updates Highlights from the 2013 ASCO Annual Meeting. Chicago, IL, USA; May 30 - June 4, 2013
HIGHLIGHT ARTICLE Neuroendocrine Tumors: Treatment Updates Highlights from the 2013 ASCO Annual Meeting. Chicago, IL, USA; May 30 - June 4, 2013 Simon Khagi, Muhammad Wasif Saif Tufts Medical Center, Tufts
More informationPNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.
GI and Pancreatic NETs The Postgraduate Course in Breast and Endocrine Surgery Disclosures Ipsen NET Advisory Board Marines Memorial Club and Hotel San Francisco, CA Eric K Nakakura San Francisco, CA March
More informationTitle: High Risk of Myelodysplastic Syndrome (MDS) and Acute Myeloid. in Neuroendocrine Tumor Patients Heavily Pre-treated with Alkylating
Page 1 of 12 Accepted Preprint first posted on 1 March 2016 as Manuscript ERC-15-0543 1 2 3 4 Title: High Risk of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) after 177 Lu-octreotate
More informationNET und NEC. Endoscopic and oncologic therapy
NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation
More informationPancreatic Neuroendocrine Tumours
UCLH Cancer Collaborative Pancreas Update Meeting 12 th July 2017 Pancreatic Neuroendocrine Tumours Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior
More informationDisclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS
More informationLanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
The new england journal of medicine original article Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors Martyn E. Caplin, D.M., Marianne Pavel, M.D., Jarosław B. Ć wikła, M.D., Ph.D., Alexandria
More informationLYON. FRANCE NOVEMBER / 2013 TRANSLATIONAL RESEARCH IN CHRONIC VIRAL HEPATITIS - BRIDGING BASIC SCIENCE AND CLINICAL RESEARCH
LYON. FRANCE NOVEMBER 29-30 / 2013 TRANSLATIONAL RESEARCH IN CHRONIC VIRAL HEPATITIS - BRIDGING BASIC SCIENCE https://events.easl.eu/eventportal/ Information/MLYON2013/HOME.aspx Abstract submission deadline:
More informationGastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute
pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 215;47(4):738-746 Original Article http://dx.doi.org/1143/crt.214.224 Open Access Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in
More informationQOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors
QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors Abstract C-33 Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday
More informationProlonged Survival in a Patient with Neuroendocrine Tumor of the Cecum and Diffuse Peritoneal Carcinomatosis
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1. Therapies for non-men1 pancreatic neuroendocrine tumours (NETs) (published after 2011) Somatostatin analogues Tumour type a Intervention Number of participants/information available
More informationClinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study
Zhang et al. BMC Endocrine Disorders 2014, 14:54 RESEARCH ARTICLE Open Access Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective
More informationABSTRACT INTRODUCTION. Chaoyong Shen 1,*, Yuan Yin 1,*, Huijiao Chen 2, Sumin Tang 1, Xiaonan Yin 1, Zongguang Zhou 1,3, Bo Zhang 1, Zhixin Chen 1
/, 2017, Vol. 8, (No. 13), pp: 22123-22134 Neuroendocrine tumors of colon and rectum: validation of clinical and prognostic values of the World Health Organization 2010 grading classifications and European
More informationESPACOMP SCIENTIFIC MEETING PROGRAM
Version 29.06.2018 SDG 22th ESPACOMP conference - Dublin, Ireland (European Society for Patient Adherence, COMpliance and Persiste nce) THURSDAY, NOVEMBER 29TH TO SATURDAY, DECEMBER 1ST, 2018 ESPACOMP
More informationDigestive and Liver Disease
Digestive and Liver Disease 44 (2012) 95 105 Contents lists available at SciVerse ScienceDirect Digestive and Liver Disease journal homepage: www.elsevier.com/locate/dld Review Article New treatment strategies
More informationManagement of Neuroendocrine Tumors
Management of Neuroendocrine Tumors Professor Barbro Eriksson Department of Endocrine Oncology ENETS Centre of Excellence Uppsala University Hospital Diagnostic Challenges in NET Heterogeneous group of
More informationLet Your Education Soar Over the Land of Enchantment
SGNO Exhibitor Prospectus 2018 Albuquerque, New Mexico March 21 st -24th Let Your Education Soar Over the Land of Enchantment Nurse Oncologists The 35th Annual Symposium of the Society of Gynecologic Nurse
More informationSystemic Therapy for Advanced Pancreatic Neuroendocrine Tumors: An Update
Focused Review 777 Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors: An Update Diane L. Reidy-Lagunes, MD, MS Abstract Well-differentiated neuroendocrine tumors (NETs) can be subdivided into
More informationTreatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece
Treatment algorithm Neuroendocrine tumours Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece Outline Presenting a meaningful algorithm Means used to develop algorithm
More informationTNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study
DOI: 10.1093/jnci/djs208 Advance Access publication on April 23, 2012. The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
More informationNeuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC
Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC Case Study 43 yr old female with a history of a left mastectomy
More informationNET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες
NETMASTERCLASS 2017: an interactive workshop NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες Νικόλαος Τσουκαλάς MD, MSc, PhD Ογκολόγος - Παθολόγος, MSc Βιοπληροφορική Επιμελητής Α, Ογκολογικό Τμήμα Νοσηλευτικό
More informationCase Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT
Case Report 8-YEAR SURVIVAL WITH A METASTATIC THYMIC NEUROENDOCRINE TUMOR: EMPHASIS ON REDEFINING TREATMENT OBJECTIVES USING PERSONALIZED PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 177 Lu- AND 90 Y-LABELED
More informationNEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)
NEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Cynthia Card (Staff Medical Oncologist, University of Calgary)
More informationLABORATORY ANIMAL SCIENCE ASSOCIATION. Information Booklet
LABORATORY ANIMAL SCIENCE ASSOCIATION Information Booklet Platinum Sponsor: Gold Sponsors: Silver Sponsors: Bronze Sponsors: Welcome! We are pleased to invite you to Birmingham for the 2017 LASA Annual
More informationNuevas alternativas en el manejo de TNE avanzados
Nuevas alternativas en el manejo de TNE avanzados Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla,
More informationConference on Philanthropy 2019: Responsive Philanthropy
Conference on Philanthropy 2019: Responsive Philanthropy May 22-24, 2019 Washington Marriott at Metro Center Washington, DC The International Association of Advisors in Philanthropy (AiP) is proud to present
More information13 th Congress of the European Hip Society
13 th Congress of the European Hip Society Congress President: Dr. Berend Willem Schreurs, Nijmegen CALL FOR ABSTRACTS 20 22 September 2018 The Hague, The Netherlands www.ehs-congress.org 13 th Congress
More informationInfos:
SPRING MEETING SWISS SOCIETY OF PHARMACOLOGY & TOXICOLOGY Pharmacology and Toxicology of Ageing: Integrating education from basic research to clinical science April 19, 2012 Inselspital Bern Infos: http://www.swisspharmtox.ch
More informationPractical management and treatment of pancreatic neuroendocrine tumors
Review Article Practical management and treatment of pancreatic neuroendocrine tumors Naoko Iwahashi Kondo, Yasuharu Ikeda Department of Gastroenterological Surgery, National Hospital Organization Kyushu
More informationoncology For 9 th eso-esmo course on July 2012 ioannina, Greece
ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA ioannina 21/07/12 9 th eso-esmo course on oncology For medical students 21-27 July 2012 ioannina, Greece chair: N. Pavlidis, GR core faculty: R.A. Audisio, UK
More informationChromogranin A as a Marker for Diagnosis, Treatment, and Survival in Patients With Gastroenteropancreatic Neuroendocrine Neoplasm
Chromogranin A as a Marker for Diagnosis, Treatment, and Survival in Patients With Gastroenteropancreatic Neuroendocrine Neoplasm Yu-hong Wang, PhD, Qiu-chen Yang, MD, Yuan Lin, MD, PhD, Ling Xue, MD,
More informationESPE Science School (ESS) May 16-20, Heraklio, Crete, Greece
ESPE Science School (ESS) May 16-20, 2012 - Heraklio, Crete, Greece November 27, 2011 Dear ESPE member, RE: Call for ESS Student applications This is our annual call for ESPE members to have their younger
More information